Your browser doesn't support javascript.
loading
Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis.
Radwanska, Agata; Cottage, Christopher Travis; Piras, Antonio; Overed-Sayer, Catherine; Sihlbom, Carina; Budida, Ramachandramouli; Wrench, Catherine; Connor, Jane; Monkley, Susan; Hazon, Petra; Schluter, Holger; Thomas, Matthew J; Hogaboam, Cory M; Murray, Lynne A.
Affiliation
  • Radwanska A; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Cottage CT; Bioscience COPD/IPF, Research and Early Development, R&I, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Piras A; Bioscience In Vivo, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Overed-Sayer C; Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Sihlbom C; Proteomics Core Facility of Sahlgrenska Academy, University of Gothenburg, Sweden.
  • Budida R; Translational Science and Experimental Medicine, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Wrench C; Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Connor J; Bioscience COPD/IPF, Research and Early Development, R&I, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Monkley S; Translational Science and Experimental Medicine, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hazon P; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Schluter H; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Thomas MJ; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Hogaboam CM; Cedar-Sinai, Los Angeles, California, USA.
  • Murray LA; Bioscience COPD/IPF, Research and Early Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
JCI Insight ; 7(16)2022 08 22.
Article de En | MEDLINE | ID: mdl-35993367
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic disease of unmet medical need. It is characterized by formation of scar tissue leading to a progressive and irreversible decline in lung function. IPF is associated with repeated injury, which may alter the composition of the extracellular matrix (ECM). Here, we demonstrate that IPF patient-derived pulmonary ECM drives profibrotic response in normal human lung fibroblasts (NHLF) in a 3D spheroid assay. Next, we reveal distinct alterations in composition of the diseased ECM, identifying potentially novel associations with IPF. Growth differentiation factor 15 (GDF15) was identified among the most significantly upregulated proteins in the IPF lung-derived ECM. In vivo, GDF15 neutralization in a bleomycin-induced lung fibrosis model led to significantly less fibrosis. In vitro, recombinant GDF15 (rGDF15) stimulated α smooth muscle actin (αSMA) expression in NHLF, and this was mediated by the activin receptor-like kinase 5 (ALK5) receptor. Furthermore, in the presence of rGDF15, the migration of NHLF in collagen gel was reduced. In addition, we observed a cell type-dependent effect of GDF15 on the expression of cell senescence markers. Our data suggest that GDF15 mediates lung fibrosis through fibroblast activation and differentiation, implicating a potential direct role of this matrix-associated cytokine in promoting aberrant cell responses in disease.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Matrice extracellulaire / Fibrose pulmonaire idiopathique / Facteur-15 de croissance et de différenciation Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: JCI Insight Année: 2022 Type de document: Article Pays d'affiliation: Suède

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Matrice extracellulaire / Fibrose pulmonaire idiopathique / Facteur-15 de croissance et de différenciation Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: JCI Insight Année: 2022 Type de document: Article Pays d'affiliation: Suède